STOCK TITAN

Nutriband Inc - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Overview

Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.

Advanced Abuse-Deterrent Technology

The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.

Business Model and Operations

Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.

Strategic Partnerships and Intellectual Property

A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.

Market Position and Industry Significance

Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.

Product Portfolio and Future Applications

While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.

Commitment to Safety and Regulatory Compliance

At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.

Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced it has completed the necessary steps to submit its application to Ecuador's Health Register, allowing for the distribution of medical devices and cosmetic products in South America. This move opens access to the Andean Community, which includes four countries: Colombia, Ecuador, Peru, and Bolivia, with a combined population exceeding 114 million. Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse-deterrent fentanyl patch utilizing AVERSA™ technology. The company is navigating various risks associated with product development and regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) is showcasing its innovations at the 2023 Transdermal and Microneedle Conference in London on January 23-24, 2023. CEO Gareth Sheridan will present on January 24 at 11:00 a.m. GMT, focusing on enhancing transdermal technologies to minimize liability regarding abusable medications. COO Dr. Alan Smith will join a panel discussion at 11:40 a.m. GMT about microneedle applications in drug delivery. The conference will also feature industry leaders including Merck and GSK. Nutriband's AVERSA technology aims to prevent drug abuse, emphasizing safety in chronic pain treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
conferences
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has dual-listed on Upstream, a platform for digital securities and NFTs, enhancing its accessibility to global investors. The listing became effective on January 5, 2023, allowing trades in real-time through Upstream's transparent order book. A commemorative NFT for this listing is also available. CEO Gareth Sheridan emphasized the listing's value for shareholders and the company’s mission to reach a modern investor base. However, U.S. investors are only allowed to liquidate existing holdings on Upstream.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its dual listing on Upstream, commencing January 5, 2023. This move positions Nutriband as the first company to utilize Upstream's platform, allowing global investors to trade using various payment methods, including USDC digital currency. The dual listing aims to enhance liquidity, price discovery, and accessibility for U.S. investors. Nutriband's primary focus is developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA™ technology, which is crucial for preventing drug abuse.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its approval for a dual listing on Upstream, with trading set to begin on January 5, 2023. This move aims to enhance liquidity and broaden its investor base by allowing trading in digital currencies like USDC and traditional payment methods. Participants will also receive a commemorative NFT on listing day. CEO Gareth Sheridan highlighted that this listing will facilitate reaching international markets and bolster shareholder value as the company develops its AVERSA™ technology for transdermal products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) will feature on The RedChip Money Report on Bloomberg TV, airing December 17, 2022, at 7 p.m. ET. The interview will showcase Nutriband's transdermal technology and its applications, led by Chief Scientific Officer Dr. Jeff Patrick. This technology includes the development of an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The segment will be accessible to an estimated 73 million U.S. homes. For full access to the interview, visit here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported a record revenue of $620,000 for Q3 2022, marking a 118% increase from Q3 2021. Year-to-date revenue reached $1,552,074, a 67% year-over-year growth. The company continues to expand its AVERSA™ intellectual property portfolio with patents granted in 44 countries. Net loss decreased to $1.07 million from $1.57 million in the prior year. CEO Gareth Sheridan highlighted potential peak sales for AVERSA Fentanyl could range between $80 million to $200 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
-
Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will present at the RHK Capital Disruptive Growth Conference on December 5, 2022, at 10:20 AM in New York City. The presentation will focus on the company's AVERSA technology and its market potential. The conference will host executives from up to 30 growth-oriented companies, engaging with institutional investors and financial advisors. Nutriband specializes in transdermal pharmaceutical products, with a lead product under development being an abuse deterrent fentanyl patch utilizing AVERSA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
Rhea-AI Summary

Nutriband Inc. (NTRB, NTRBW) announced the granting of Canadian patent No. 2,937,649 for its AVERSA™ transdermal abuse deterrent technology. The patent issued on November 1, 2022, enhances protection for the AVERSA™ products across North America, following similar patents granted in the U.S. and Mexico. This technology aims to mitigate opioid abuse, particularly in light of Canada's opioid crisis. Nutriband's AVERSA™ Fentanyl system is projected to achieve peak U.S. sales between $80M and $200M, addressing a significant public health issue while ensuring patient access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none

FAQ

What is the current stock price of Nutriband (NTRB)?

The current stock price of Nutriband (NTRB) is $5.78 as of April 1, 2025.

What is the market cap of Nutriband (NTRB)?

The market cap of Nutriband (NTRB) is approximately 63.4M.

What is Nutriband Inc's core business?

Nutriband Inc focuses on the development of transdermal pharmaceutical products using innovative abuse-deterrent technology. The company is dedicated to enhancing patient safety by preventing the misuse and accidental exposure of drugs with abuse potential.

How does the AVERSA technology work?

AVERSA technology incorporates aversive agents into transdermal patches to deter drug abuse by triggering an immediate taste aversion. This approach reduces the likelihood of misuse, diversion, or accidental ingestion of potent medications.

What are the key revenue streams for Nutriband Inc?

The company generates revenue primarily through the sale of consumer transdermal and coated products, as well as through its contract manufacturing services via its subsidiary, Pocono Pharma. These diversified streams support both product development and manufacturing partnerships.

How does Nutriband position itself within the pharmaceutical industry?

Nutriband occupies a strategic niche in the pharmaceutical sector by targeting the critical issue of drug abuse. Its advanced abuse-deterrent technology and robust intellectual property portfolio distinguish its products, particularly in addressing opioid-related safety concerns.

What strategic partnerships support Nutriband's operations?

Nutriband collaborates with respected industry partners like Kindeva Drug Delivery and Pocono Pharma. These partnerships enhance its manufacturing capabilities and ensure compliance with regulatory standards, broadening its market reach.

In which markets are Nutriband's products available?

While Nutriband is based in the United States, its operations and intellectual property extend globally, covering key markets in Europe, Japan, Australia, and more. The company’s strategic licensing and distribution agreements support international market penetration.

How is Nutriband addressing the opioid crisis?

Nutriband is developing abuse-deterrent transdermal solutions specifically designed to mitigate opioid misuse. By incorporating aversive agents into its patches, the company aims to prevent both intentional abuse and accidental exposure.

How does Nutriband protect its innovative technology?

The company maintains a comprehensive global intellectual property portfolio with patents issued in over 40 countries. This extensive protection secures its AVERSA technology and reinforces its competitive advantage in the transdermal pharmaceutical space.
Nutriband Inc

Nasdaq:NTRB

NTRB Rankings

NTRB Stock Data

63.42M
3.30M
70.29%
2.1%
2.53%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO